Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omega-3 fatty acids are long-chain polyunsaturated fatty acids (PUFAs), primarily consisting of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). They are widely recognized for their anti-inflammatory, anti-aggregatory, and lipid-lowering properties. In the clinical context of Polycystic Ovary Syndrome (PCOS), omega-3 supplementation is investigated for its potential to improve metabolic syndrome parameters, including insulin resistance, dyslipidemia, and systemic inflammation. This specific research program, conducted by **Bangabandhu Sheikh Mujib Medical University (BSMMU)** in Dhaka, Bangladesh, utilizes a randomized, double-blind, placebo-controlled design to evaluate the efficacy of omega-3 fatty acids in women with newly diagnosed PCOS, focusing on metabolic and endocrine stabilization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on omega-3 fatty acids (Bangabandhu Sheikh Mujib Medical University).